Wells Fargo & Co restated their outperform rating on shares of Johnson & Johnson (NYSE:JNJ) in a research note released on Friday, Marketbeat.com reports. They currently have a $160.00 price target on the stock, up from their previous price target of $155.00.

Several other brokerages have also recently commented on JNJ. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an outperform rating in a research report on Thursday, October 19th. Vetr upgraded shares of Johnson & Johnson from a hold rating to a buy rating and set a $147.40 price target for the company in a research report on Monday, January 1st. Royal Bank of Canada lifted their price target on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an outperform rating in a research report on Wednesday, October 18th. Citigroup started coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They set a neutral rating and a $140.00 price objective on the stock. Finally, Goldman Sachs Group lowered shares of Johnson & Johnson from a neutral rating to a sell rating and lifted their price objective for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson currently has a consensus rating of Hold and an average target price of $145.94.

Shares of Johnson & Johnson (NYSE JNJ) traded up $1.30 during trading hours on Friday, hitting $147.06. 1,494,589 shares of the stock traded hands, compared to its average volume of 6,020,711. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $146.42. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The firm has a market cap of $395,380.00, a PE ratio of 25.53, a price-to-earnings-growth ratio of 2.75 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the previous year, the company earned $1.68 EPS. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. sell-side analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.28%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s payout ratio is currently 58.33%.

A number of institutional investors and hedge funds have recently made changes to their positions in JNJ. Harding Loevner LP bought a new stake in shares of Johnson & Johnson in the second quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. lifted its position in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares in the last quarter. IHT Wealth Management LLC lifted its position in shares of Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new stake in shares of Johnson & Johnson in the second quarter worth $124,000. 65.71% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson’s (JNJ) “Outperform” Rating Reiterated at Wells Fargo & Co” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/johnson-johnsons-jnj-outperform-rating-reiterated-at-wells-fargo-co/1809235.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.